<DOC>
	<DOCNO>NCT02474680</DOCNO>
	<brief_summary>This non-randomized , single-case design pharmacogenetic implementation mental health patient population subject take antipsychotic and/or antidepressant .</brief_summary>
	<brief_title>Evaluation Pharmacogenetic Testing In Mental Health Population Economic Outcomes</brief_title>
	<detailed_description>This non-randomized , single-case design pharmacogenetic implementation mental health patient population subject take antipsychotic and/or antidepressant . Retrospective prospective data collect subject pharmacogenetic recommendation make . Retrospective data collect previous 12 month pharmacogenetic recommendation make prospective data collect 12 month pharmacogenomic recommendation make .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Must take either antidepressant antipsychotic medication Must provide inform consent Must Avera Health Plans insurance coverage Must three month participation Avera Care Coordination Program Must pregnant breastfeeding Must active and/or unstable diagnosis substance abuse Must primary diagnosis dementia , bulimia , anorexia nervosa disorder Must previous pharmacogenetic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>mental health</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>personalize medicine</keyword>
	<keyword>precision medicine</keyword>
	<keyword>anti-depressants</keyword>
</DOC>